Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

We hypothesized that short-term treatment with haloperidol induces insulin resistance through a mechanistic route that is independent of weight gain. We therefore treated healthy non-obese men with haloperidol for 8 days, and studied the impact of these intervention on glucose and lipid metabolism by hyperinsulinemic euglycemic clamp, isotope dilution technology and indirect calorimetry.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Leiden University Medical Center
• Collaborator: Dutch Diabetes Research Foundation
• Treatments: Dopamine; Haloperidol; Haloperidol decanoate

Criteria

Inclusion Criteria:

• Healthy men

• 20 kg/m2 < BMI < 26 kg/m2

• Age 20-40 years

• FPG < 6 mmol/L

Exclusion Criteria:

• FPG > 6 mmol/L

• BMI > 26 kg/m2

• Psychiatric disorders and/or use of antipsychotic or antidepressants drugs at present or in the past.

• A positive family history of schizophrenia

• Any significant chronic disease

• Renal, hepatic or endocrine disease

• Use of medication known to influence lipolysis and/or glucose metabolism

• Total cholesterol > 7mmol/L and/or triglycerides > 2 mmol/L

• Recent weight changes or attempts to loose weight (> 3 kg weight gain or loss, within the last 3 months)

• Difficulties to insert an intravenous catheter

• Smoking (current)

• Severe claustrophobia (ventilated hood)

• Recent blood donation (within the last 2 months)

• Recent participation in other research projects (within the last 3 months), participation in 2 or more projects in one year

• Extensive sporting activities (more than 10 hours of exercise per week)